That’s Pfizer’s Abrysvo, which was approved in May for adults over 60. This indication is intended to protect the baby during the first six months of life.
America becomes the first country Respiratory syncytial virus (RSV) vaccine approved for pregnant women to prevent bronchiolitis in infants. The country’s Food and Drug Administration (FDA) issued a statement on August 21 approving Pfizer’s Abrysvo for use during the 32nd to 36th week of pregnancy.
It is given as a single intramuscular injection and when administered in a pregnant woman will keep the baby protected for the first six months of life.
The virus, he recalls, “is a common cause of illness in children, and infants are among the most vulnerable to severe illness, which can lead to hospitalization.” peter marquesDirector of FDA’s Center for Biological Research and Evaluation.
The clinical trial involving about 7,000 pregnant women showed that the vaccine, called Abrysvo, It reduced severe variant disease by 82% in infants 0 to 3 months and by 69% in infants 0 to 6 months.
RSV usually causes mild cold-like symptoms in infants and young children, and can also cause pneumonia and bronchiolitis. According to the US Centers for Disease Control and Prevention (CDC), an estimated 58,000 to 80,000 children under the age of 5 are hospitalized with RSV infection, making it the leading cause of hospitalization in infants.